MedTrace Logo

Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

NCT06301945 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1020

Last updated 2024-03-27

No results posted yet for this study

Summary

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.

In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.

The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.

In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.

The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

Conditions

  • Thymic Epithelial Tumor
  • Thymic Carcinoma
  • Thymoma
  • Thymoma and Thymic Carcinoma

Interventions

DIAGNOSTIC_TEST

Artificial Intelligence Diagnostics

AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.

DIAGNOSTIC_TEST

Recurrence Prediction Tool

This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.

Sponsors & Collaborators

  • Maastro Clinic, The Netherlands

    collaborator OTHER

  • Hospices Civils de Lyon

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2027-08-01
Completion
2027-08-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301945 on ClinicalTrials.gov